Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS
Oncol Rep. 2024 Jan;51(1):17. doi: 10.3892/or.2023.8676. Epub 2023 Dec 8.ABSTRACTPVRL4 (or nectin‑4) is a promising therapeutic target since its upregulated expression is found in a wide range of human cancer types. Enfortumab vedotin, an antibody‑drug conjugate targeting PVRL4, is clinically used for the treatment of urothelial bladder cancer. In addition, rMV‑SLAMblind, a genetically engineered oncolytic measles virus, can infect cancer cells and induce apoptosis through interaction with PVRL4. Although PVRL4 transcript levels are elevated in breast, lung and ovarian cancer, the mechanisms of its upregulation have ...
Source: Oncology Reports - December 8, 2023 Category: Cancer & Oncology Authors: Tomoyuki Nanamiya Kiyoko Takane Kiyoshi Yamaguchi Yuya Okawara Mariko Arakawa Akari Saku Tsuneo Ikenoue Tomoko Fujiyuki Misako Yoneda Chieko Kai Yoichi Furukawa Source Type: research
The advance of the third ‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)
Oncol Rep. 2024 Jan;51(1):16. doi: 10.3892/or.2023.8675. Epub 2023 Dec 8.ABSTRACTLung cancer is currently the second most common type of cancer with the second incidence rate and the first mortality rate worldwide. Non‑small cell lung cancer (NSCLC) accounts for ~85% of the total number of cases of lung cancers. Concerning the treatment of NSCLC, targeted therapy has become a research hotspot in recent years because of its favorable efficacy, high selectivity and minimal adverse reactions. Among the drugs used in targeted therapy, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the most ...
Source: Oncology Reports - December 8, 2023 Category: Cancer & Oncology Authors: Zhinan Cheng Hongwei Cui Yaqi Wang Jin Yang Chunyang Lin Xiaoyu Shi Yuxiu Zou Jing Chen Xiaoqiong Jia Liqing Su Source Type: research
[Retracted] Effects of miR ‑138‑5p and miR‑204‑5p on the migration and proliferation of gastric cancer cells by targeting EGFR
Oncol Rep. 2024 Feb;51(2):18. doi: 10.3892/or.2023.8677. Epub 2023 Dec 8.ABSTRACTFollowing the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that the numerous immunohistochemical images shown in Fig. 1D on p. 2626 exhibited a number of overlaps comparing among the data panels, such that data which were intended to show the results from differently performed experiments were likely to have been derived from a smaller number of original sources. A subsequent independent investigation of the data in this paper in the Editorial Office also revealed that certain of the cell migrati...
Source: Oncology Reports - December 8, 2023 Category: Cancer & Oncology Authors: Yi Wang Haiyang Zhang Shaohua Ge Qian Fan Likun Zhou Hongli Li Ming Bai Tao Ning Rui Liu Xia Wang Ting Deng Le Zhang Guoguang Ying Yi Ba Source Type: research
Expression of PVRL4, a molecular target for cancer treatment, is transcriptionally regulated by FOS
Oncol Rep. 2024 Jan;51(1):17. doi: 10.3892/or.2023.8676. Epub 2023 Dec 8.ABSTRACTPVRL4 (or nectin‑4) is a promising therapeutic target since its upregulated expression is found in a wide range of human cancer types. Enfortumab vedotin, an antibody‑drug conjugate targeting PVRL4, is clinically used for the treatment of urothelial bladder cancer. In addition, rMV‑SLAMblind, a genetically engineered oncolytic measles virus, can infect cancer cells and induce apoptosis through interaction with PVRL4. Although PVRL4 transcript levels are elevated in breast, lung and ovarian cancer, the mechanisms of its upregulation have ...
Source: Oncology Reports - December 8, 2023 Category: Cancer & Oncology Authors: Tomoyuki Nanamiya Kiyoko Takane Kiyoshi Yamaguchi Yuya Okawara Mariko Arakawa Akari Saku Tsuneo Ikenoue Tomoko Fujiyuki Misako Yoneda Chieko Kai Yoichi Furukawa Source Type: research
Oncogenic role of FOXM1 in human prostate cancer (Review)
Oncol Rep. 2024 Jan;51(1):15. doi: 10.3892/or.2023.8674. Epub 2023 Dec 1.ABSTRACTProstate cancer is the leading cause of cancer‑related mortality among men worldwide. In particular, castration‑resistant prostate cancer presents a formidable clinical challenge and emphasizes the need to develop novel therapeutic strategies. Forkhead box M1 (FOXM1) is a multifaceted transcription factor that is implicated in the acquisition of the multiple cancer hallmark capabilities in prostate cancer cells, including sustaining proliferative signaling, resisting cell death and the activation of invasion and metastasis. Elevated FOXM1 ...
Source: Oncology Reports - December 1, 2023 Category: Cancer & Oncology Authors: Da Young Lee Jung Nyeo Chun Insuk So Ju-Hong Jeon Source Type: research
